Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.6850 (-9.42%) ($6.6850 - $6.6850) on Thu. Sep. 2, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.35% (three month average) | RSI | 59 | Latest Price | $6.6850(-9.42%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.1% a day on average for past five trading days. | Weekly Trend | HTBX advances 5.7% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(52%) XBI(52%) ARKK(50%) ONLN(49%) IBUY(48%) | Factors Impacting HTBX price | HTBX will decline at least -4.175% in a week (0% probabilities). VIXM(-33%) VXX(-28%) UUP(-14%) TLT(-10%) XLU(-9%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.175% (StdDev 8.35%) | Hourly BBV | -1.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $7.03(-4.91%) | 10 Day Moving Average | $6.84(-2.27%) | 20 Day Moving Average | $6.65(0.53%) | To recent high | -37.8% | To recent low | 8.3% | Market Cap | $736m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |